Office of Research & Development |
  |
Talk to the Veterans Crisis Line now
An official website of the United States government
Project Number: | I01CX001449-01A1 |
| Title: | Frequent, Low-Dose Erythropoietin: A Mechanistic Approach to Mitigate Adverse Cardiovascular Effects of Erythropoietin Therapy in Patients with Chronic Kidney Disease |
| Principal Investigator: | Mark S. Segal |
| Location: | Gainesville, FL |
| Congressional District Code: | 3 |
| Research Service: | Clinical Science R&D |
| Project Period: | October 2017 - September 2022 |
| FY 2021 Funding Amount: | $0 |
| Total Award Amount (all years): |
$401,473 |
| Abstract: |
View full abstract and other project information on NIH RePORTER Go To NIH RePORTER Excerpt: Erythropoietin is the most widely prescribed cytokine, yet the benefits and potential side effects of different dosing regimens are poorly understood. Clinically, it is now recognized that erythropoietin administered at high doses results in an increased probability of cancer recurrence and in patients with chronic kidney disease, an increased risk of morbidity and mortality from heart disease and stroke. However, the mechanisms that mediate this increased risk of cardiovascular disease is not k... |